Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

Background Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the pharmacologic profile and clinical outcomes for mavacamten and aficamten, 2 cardiac myos...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Bryton J. Davis, Hailey Volk, Olives Nguyen, Daniel Kamna, Hongya Chen, Roberto Barriales‐Villa, Pablo Garcia‐Pavia, Iacopo Olivotto, Anjali T. Owens, Caroline J. Coats, Theodore P. Abraham, Scott D. Solomon, Martin S. Maron, Ahmad Masri
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2025-03-01
Edice:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Témata:	aficamten cardiac myosin inhibitors mavacamten symptomatic hypertrophic cardiomyopathy
On-line přístup:	https://www.ahajournals.org/doi/10.1161/JAHA.124.038758
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!